A study out of Israel has concluded heart attack survivors with an active sex life are better off than their less-active counterparts in the years following an MI, Reuters Health reported August 1.

In patients with both type 2 diabetes and an elevated cardiovascular risk, metformin lowers the risk of all-cause mortality but does little to protect against CV death, MI or ischemic stroke, a new evaluation of the SAVOR-TIMI 53 trial has found.

An editorial published in The Lancet August 2 scrutinized JUUL Labs’ participation in and sponsorship of e-cigarette research in the U.S., finding the vaping giant fell short in seven of eight categories designed to test ethical integrity.

Non-selective His bundle pacing is noninferior to selective HBP in patients undergoing de novo permanent pacemaker implantation for bradycardia, according to a study that revealed similar outcomes for death and HF between the two therapies.

Individuals infected with hepatitis C are at a significantly increased risk of developing heart disease, according to a Lancet analysis that also found hep C-linked CVD is responsible for 1.5 million disability-adjusted life-years (DALYs) annually.

Wellness company Hello Heart has raised $12 million in new funding that will go toward developing at-home monitoring solutions and behavioral treatments for hypertension, TechCrunch reported July 31.

Researchers at the Carnegie Institution for Science, Johns Hopkins University and the Mayo Clinic have reportedly leveraged “state-of-the-art” genome editing to track lipoprotein movement in real time, allowing scientists a glimpse into how cholesterol moves, accumulates and gathers to build plaque.

An antioxidant compound found in soybeans might protect the heart from cannabis-related CV damage, according to work presented at the American Heart Association’s Basic Cardiovascular Sciences 2019 Scientific Sessions.